Home
SCYX
SCYX News

Latest SCYNEXIS Inc. (SCYX) News on June 2, 2025

Will Tesla have to play catch up to Waymo's robotaxis?

Yahoo Finance Video

a day ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys

Yahoo Finance

a day ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

a day ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

a day ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

PR Newswire

a day ago

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

Statement by Minister Guilbeault on Portuguese Heritage Month

CNW Group

a day ago

Statement by Minister Guilbeault on Portuguese Heritage Month

Man Utd sign Brazil forward Cunha from Wolves

AFP

a day ago

Man Utd sign Brazil forward Cunha from Wolves

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

Moneywise

a day ago

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

Insider Monkey

4 days ago

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

Scynexis resumes dosing in Phase III MARIO study after lengthy delay

Clinical Trials Arena

5 days ago

Scynexis resumes dosing in Phase III MARIO study after lengthy delay

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

GlobeNewswire

5 days ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

GlobeNewswire

2 months ago

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

3 months ago

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

3 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

GlobeNewswire

5 months ago

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

7 months ago

SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Associated Press Finance

7 months ago

Scynexis: Q3 Earnings Snapshot

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

7 months ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

Simply Wall St.

7 months ago

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

8 months ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

GuruFocus.com

8 months ago

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

GlobeNewswire

8 months ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

9 months ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

10 months ago

SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Associated Press Finance

10 months ago

Scynexis: Q2 Earnings Snapshot

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

10 months ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

GlobeNewswire

10 months ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

Associated Press Finance

a year ago

Scynexis: Q1 Earnings Snapshot

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

Simply Wall St.

a year ago

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

GlobeNewswire

a year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

GlobeNewswire

a year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

GlobeNewswire

a year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

GuruFocus.com

a year ago

MetroCity Bankshares Inc Reports Mixed Results for Q4 and Full Year 2023

Associated Press Finance

a year ago

MetroCity: Q4 Earnings Snapshot

METROCITY BANKSHARES, INC. REPORTS EARNINGS FOR FOURTH QUARTER AND YEAR ENDED 2023

PR Newswire

a year ago

METROCITY BANKSHARES, INC. REPORTS EARNINGS FOR FOURTH QUARTER AND YEAR ENDED 2023

Mama’s Creations to Ring Nasdaq Closing Bell on Tuesday, January 23, 2024

GlobeNewswire

a year ago

Mama’s Creations to Ring Nasdaq Closing Bell on Tuesday, January 23, 2024

New research warns of emerging "AI Gap" between brands and consumers

PR Newswire

a year ago

New research warns of emerging "AI Gap" between brands and consumers

OFS Credit Company Provides December 2023 Net Asset Value Update

Business Wire

a year ago

OFS Credit Company Provides December 2023 Net Asset Value Update

Oil Prices Weighed Down by Massive Build in Fuel Inventories

Zacks

a year ago

Oil Prices Weighed Down by Massive Build in Fuel Inventories

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

GlobeNewswire

a year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

PLBY Group to Participate in the 2024 ICR Conference

GlobeNewswire

a year ago

PLBY Group to Participate in the 2024 ICR Conference

Electrovaya Begins Shipping Infinity-HV Battery Systems

ACCESSWIRE

a year ago

Electrovaya Begins Shipping Infinity-HV Battery Systems

Brightcove Appoints New CMO and CRO, Creates COO Position

Business Wire

a year ago

Brightcove Appoints New CMO and CRO, Creates COO Position

FVCBankcorp (FVCB) Soars 5.9%: Is Further Upside Left in the Stock?

Zacks

a year ago

FVCBankcorp (FVCB) Soars 5.9%: Is Further Upside Left in the Stock?

Syntec Optics Expands Thin-Film Technology with Gold Coating Capabilities (Nasdaq: OPTX)

GlobeNewswire

a year ago

Syntec Optics Expands Thin-Film Technology with Gold Coating Capabilities (Nasdaq: OPTX)

Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

Simply Wall St.

2 years ago

Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

11 Cheapest Stocks With Biggest Upside

Insider Monkey

2 years ago

11 Cheapest Stocks With Biggest Upside

Unlocking Financial Freedom: The Power of Flex CDs in Today's Economy

PR Newswire

2 years ago

Unlocking Financial Freedom: The Power of Flex CDs in Today's Economy

5 Struggling Stocks to Buy at a Discount

Motley Fool

2 years ago

5 Struggling Stocks to Buy at a Discount

Associated Press Finance

2 years ago

Scynexis: Q3 Earnings Snapshot

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire

2 years ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

GlobeNewswire

2 years ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

CORRECTING AND REPLACING: NOVONIX Finalizes US$100 Million Grant Award from U.S. Department of Energy

GlobeNewswire

2 years ago

CORRECTING AND REPLACING: NOVONIX Finalizes US$100 Million Grant Award from U.S. Department of Energy

Positive Signs As Multiple Insiders Buy Relmada Therapeutics Stock

Simply Wall St.

2 years ago

Positive Signs As Multiple Insiders Buy Relmada Therapeutics Stock

Share on Social Networks: